Items Tagged ‘herceptin’

July 27th, 2016

Neratinib Improves Cancer-Free Survival in Early Breast Cancer

By

The targeted agent neratinib (PB272), which is still in clinical trials, demonstrated an improvement in cancer-free survival when used after Herceptin® (trastuzumab) in early-stage, HER2-positive breast cancer. Approximately 20-30% of breast cancer is referred to as human epidermal growth factor receptor-2 (HER2)-positive.  This means that the breast cancer cells have too many HER2 proteins on […]

View full entry

Tags: Breast Cancer, early breast cancer, exteNET, HER2-positive, herceptin, neratinib, News, Stage I Node Negative Breast Cancer, Stages II-III Breast Cancer, trastuzumab. her2


May 11th, 2016

Herceptin® Plus Tykerb® Promising for HER2-Positive Colorectal Cancer

By

The treatment combination consisting of Herceptin (trastuzumab) plus Tykerb (lapatinib) provides significant anti-cancer activity in colorectal cancer that overexpresses the human epidermal growth factor receptor 2 (HER2). These results were recently published in The Lancet Oncology. The HER2 receptor is a protein that is normally found on the surface of several different types of cells […]

View full entry

Tags: Colon Cancer, colorectal cancer, HER2-positive, herceptin, lapatinib, News, Rectal Cancer, trastuzumab, Tykerb


March 24th, 2015

Herceptin Superior to Tykerb for Treatment of HER2-positive Breast Cancer

By

In patients with human epidermal growth factor receptor (HER2)–positive advanced breast cancer, the combination of Herceptin® (trastuzumab) plus a taxane resulted in delayed time to cancer progression and was associated with fewer side effects than Tykerb® (lapatinib) plus a taxane, according to final clinical trial results reported in the Journal of Clinical Oncology. The HER2 […]

View full entry

Tags: Breast Cancer, HER2, herceptin, lapatinib, Metastatic Breast Cancer, News, Stages II-III Breast Cancer, trastuzumab, Tykerb


February 5th, 2015

Afinitor® plus Herceptin® and Paclitaxel Effective in Advanced Hormone Receptor-Negative HER2-Positive Breast Cancer

By

The combination of Afinitor® (everolimus) plus Herceptin® (trastuzumab) paclitaxel appears effective for patients with advanced HER2-positive breast cancer that is hormone receptor (HR)-negative. These findings were presented at the 2014 San Antonio Breast Cancer Symposium, December 9–13, in San Antonio, Texas. Afinitor is an oral medication that works by inhibiting a protein known as mTOR. […]

View full entry

Tags: afinitor, Breast Cancer, herceptin, paclitaxel


October 9th, 2014

Impressive Survival Gains with New First-Line Therapy for HER2-Positive Metastatic Breast Cancer

By

According to recent findings, the combination of targeted agents Herceptin® (trastuzumab) and Perjeta® (perjeta) significantly improves survival for patients with HER2-positive metastatic breast cancer when added to chemotherapy. This data was presented at the 2014 European Society for Medical Oncology (ESMO) Congress in Madrid, Spain, September 26–30.[1] HER2 is a protein involved in normal cell […]

View full entry

Tags: Breast Cancer, HER2, herceptin, Metastatic Breast Cancer, News, perjeta, Recurrent Breast Cancer


June 10th, 2014

Tykerb and Herceptin Combination Therapy Fails to Improve Outcomes for Early Stage HER2 Breast Cancer

By

Dr. Martine Piccart-Gebhart presented results at the 2014 annual meeting of the American Society of Clinical Oncology showing that a combination treatment of Tykerb® (lapatinib) and Herceptin® (trastuzumab) offered no benefit in outcomes for early stage HER2-positive breast cancer patients. Twenty to thirty percent of breast cancers overexpress (make too much of) a protein known […]

View full entry

Tags: Breast Cancer, Carcinoma In Situ Breast cancer, HER2, herceptin, News, Stage I Node Negative Breast Cancer, Stages II-III Breast Cancer, Tykerb